Compare Adaptive Biotechnologies Corp (ADPT) vs Amplify Transformational Data Sharing ETF (BLOK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Amplify Transformational Data Sharing ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Amplify Transformational Data Sharing ETF trades at $60.92. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | BLOK | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $74.10 |
52-Week Low | $10.24 | $47.36 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BLOK trades at $63.47, up 3.07% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock faces resistance at $64 and support at $62. Recent news highlights the ETF's exposure to AI infrastructure and Bitcoin mining stocks, though analyst sentiment has turned cautious due to increased crypto market correlation.
The outlook remains neutral with technical indicators divided and fundamental data limited. Key risks include reliance on volatile crypto markets and competitive ETF pressures. Analyst consensus suggests holding pending clearer catalysts from AI infrastructure growth or Bitcoin market stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →
